Latest Breaking News On - Paris vision institute - Page 1 : comparemela.com

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

Completed enrollment in Phase 2b RELIEF trial of Licaminlimab , anti-TNF alpha eye drops in Dry Eye Disease ; topline results expected in Q2 2024Second Phase 3 trial of OCS-01 eye drops in Diabetic.

United statesEastern virginia medical schoolFrance generalSylvia cheungJoanne changElizabeth yeuCorey davisRamin tadayoniArshadm khananiMacula societyEuropean society of retina specialistsRetina research foundationRetina societySteering committeeOculis holding ag nasdaqAmerican academy of ophthalmology achievement award

SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa

SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesAmber fennellNathalie trepoDavide salviNamrata taakParis vision instituteSparingvision the companyFoundation fighting blindnessVision reaches final dose escalation stepData safety monitoring boardChief executive officerInvestigational new drugRetinitis pigmentosaIntellia therapeuticsAdvent france biotechnology

GenSight Biologics Provides Business and Financial Update

GenSight Biologics Provides Business and Financial Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomFrance generalThomas gidoinGensight biologicsGensight biologics euronextGuillaume van renterghemRegulatory agencyUniversity of pittsburgh school medicineParis vision instituteScientific adviceDrug substanceDrug productSight biologicsAlain sahelPittsburgh schoolFounding director

SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial

SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesAmber fennellAvril dalyDavide salviNamrata taakNathalie trepoJoseph martelUniversity of pittsburgh medical centerConsilium strategic communicationsNational hospitalEye centerParis vision instituteRd fundRetina internationalSparingvision the company

Long-time Collaborators Botond Roska and José-Alain Sahel

Basel, Switzerland, June 22, 2023 In recognition of their pioneering work on restoring vision to blind patients using optogenetic therapy, Botond Roska.

United statesBasel stadtFrance generalBotond roskaLinkedin institute of molecularParis vision instituteInstitute of molecularVision instituteGertrud reemtsma foundationLouis pasteur universityUniversity hospital baselUniversity of baselProfessor of the department ophthalmologyUniversity of pittsburgh school medicineMax planck societyInternational prize for translational neuroscience